344 related articles for article (PubMed ID: 31929122)
41. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Kitagawa M; Tashiro K
Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
[TBL] [Abstract][Full Text] [Related]
42. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
43. Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.
Hauser RA; Goud S; Formella AE
Clin Park Relat Disord; 2022; 6():100123. PubMed ID: 35059622
[TBL] [Abstract][Full Text] [Related]
44. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
45. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Luginger E; Wenning GK; Bösch S; Poewe W
Mov Disord; 2000 Sep; 15(5):873-8. PubMed ID: 11009193
[TBL] [Abstract][Full Text] [Related]
46. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
47. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
[TBL] [Abstract][Full Text] [Related]
48. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.
Brigham EF; Johnston TH; Brown C; Holt JDS; Fox SH; Hill MP; Howson PA; Brotchie JM; Nguyen JT
J Pharmacol Exp Ther; 2018 Nov; 367(2):373-381. PubMed ID: 30087157
[TBL] [Abstract][Full Text] [Related]
50. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
51. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Giladi N; Boroojerdi B; Surmann E
J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
[TBL] [Abstract][Full Text] [Related]
52. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
Hauser RA; Lytle J; Formella AE; Tanner CM
NPJ Parkinsons Dis; 2022 Mar; 8(1):29. PubMed ID: 35304480
[TBL] [Abstract][Full Text] [Related]
53. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
54. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
55. Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study.
Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Haruyama Y; Kobashi G; Sakakibara R; Shimo Y; Hatano T; Hattori N; Yamamoto T; Hirano S; Yamamoto T; Kuwabara S; Kaji Y; Fujita H; Kadowaki T; Hirata K
J Parkinsons Dis; 2020; 10(1):213-221. PubMed ID: 31868678
[TBL] [Abstract][Full Text] [Related]
56. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
57. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
58. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
59. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
60. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Wang CC; Wu TL; Lin FJ; Tai CH; Lin CH; Wu RM
Eur J Neurol; 2022 Apr; 29(4):1044-1055. PubMed ID: 34962701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
